We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test May Replace ELISA for Detecting Antibodies

By LabMedica International staff writers
Posted on 15 Apr 2019
A microwire-based test may replace enzyme-linked immunosorbent assay (ELISA) as the primary method to detect antibodies specific for pathogenic microorganisms in patient's sera.

Detection of viral infection is commonly performed using serological techniques like ELISA to detect antibody responses. More...
Such assays may also be used to determine the infection phase based on isotype (IgG or IgM) prevalence. However, ELISAs demonstrate limited sensitivity and are difficult to perform at the point of care.

Investigators at Colorado State University (Fort Collins, USA) have described a method for detecting antibodies against pathogenic viruses with sensitivity significantly better than ELISA. Their method reportedly enables label-free, rapid detection of ultra-low concentrations of virus specific antibodies.

The simple test comprised a capacitive biosensor that incorporated gold microwires coated with Zika or Chikungunya virus envelope antigen. An electrical current passed through the wire created a charge on the wire. Antibodies from the patient's sample bound to the viral proteins on the wire, which increased the outside mass. In addition, antibody binding increased the ability of the wire to hold the charge. By measuring the change in mass, it was possible to quantify the number of antibodies on the surface of the wire.

The investigators reported that with little discernable nonspecific binding, the sensor could detect as few as 10 antibody molecules in a small volume (30 microliters) of fluid within a few minutes. It could also be used to rapidly, specifically, and accurately determine the isotype of antigen-specific antibodies.

"This type of research project is something that none of us could do on our own," said senior author Dr. Brian Geiss, associate professor of microbiology, immunology, and pathology at Colorado State University. "We synergized our efforts to come up with new solutions to problems we are hoping will eventually be used in clinical settings. We hope that it can be used for point-of-care diagnostics, and that it can be developed into a compact hand-held system that can be used in the clinic or in resource-limited areas."

The microwire antibody detection method was described in the April 15, 2019, issue of the journal Biosensors and Bioelectronics.

Related Links:
Colorado State University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Thyroid Test
Anti-Thyroid EIA Test
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.